- Liberta Partners has successfully completed novelex’ carve-out and developed own product solutions
- Revenue potentials have strongly increased since Liberta Partners acquisition
- The company looks forward to continuing this growth with H&T Presspart
Liberta Partners, a Munich based Multi-Family-Holding, has divested novelex AG (“novelex”) to H&T Presspart, a division of Heitkamp & Thumann Group. The company, based in Nidau, Switzerland, is a specialist designer and manufacturer of MedTech devices for the pharmaceutical industry.
novelex develops and manufactures complex medical devices that require high precision and technical production knowhow in clean room environments. The core competencies lie within complete customer solutions including the R&D phase, manufacturing and packaging solutions. The company has a reputation for highest quality “Made in Switzerland” and completely integrated service solutions required by the pharma and laboratory industry. Thereby, novelex provides complete product development solutions from scratch. The company produces over 38 million medical devices per annum.
Since Liberta Partners acquired novelex, revenue potentials have strongly increased driven by new product developments and focus on R&D. In parallel, Liberta Partners has completed the carve-out from the previous owner and strengthened the company together with its corporate development team.
H&T Presspart is a market leading manufacturer of drug delivery devices and components focusing on respiratory treatments, with more than 50 years‘ experience. H&T Presspart has 3 European manufacturing sites and sales offices in China, India, the U.S.A. and Uruguay. With the addition of novelex, H&T Presspart, extends its focus for pharmaceutical clients and completely integrated product solutions.
Martin Streb, CEO of novelex, said, “The collaboration with Liberta Partners as an entrepreneurial partner focused on developing companies was a true success story. Together we managed to increase production output and efficiency, drive digitization and focus the company on R&D and new product development. I would like to thank Liberta Partners for the inspiring and respectful cooperation.”.
Florian Korp and Dr. Peter Franke, both Partners at Liberta Partners added, “We are honored to have accompanied novelex and thereby helped to strengthen its excellent niche market position. H&T Presspart is the right industry partner to novelex and its employees with the ability to create further growth.”.
Christian Krätzig, President of H&T Presspart, concluded, “novelex’ business is an excellent strategic fit. The acquisition will open new opportunities to accelerate growth. novelex‘ extensive experience in the delivery of high-quality components and devices for Pharmaceutical clients complements our offering and capabilities in the growing drug delivery device market.“.
novelex AG based in Nidau, Switzerland is an integral partner of the pharmaceutical industry worldwide. As such novelex provides design, development, manufacturing, assembly and packaging services for custom medical & drug delivery solutions. The team consists of 100 employees in the segments engineering, molding, assembly, logistics and quality. For more information, please visit: www.novelex.com
About Liberta Partners
Liberta Partners is a multi-family holding based in Munich. Liberta Partners invests in companies predominately based in German-speaking countries with clear operational and strategic development potential, in particular corporate carve-outs and successions. We actively develop our investments within the framework of our long-term „100% Core & Care“ concept. Our portfolio companies thus benefit from Liberta Partners‘ innovative entrepreneurial experience. The Liberta Partners team consists of professionals covering the areas of M&A, Corporate Development and Legal as well as an active advisory board. For more information, please visit: www.liberta-partners.com
About H&T Presspart
H&T Presspart is a market leading manufacturer of drug delivery devices and components focusing on respiratory treatments, with more than 50 years‘ experience and enjoys a worldwide reputation for competence, quality and innovation in the pharmaceutical market. H&T Presspart’s New Product Development Center (NPDC) and Inhalation Product Technology Centre (IPTC) support our customer’s new product developments and strategic initiatives. H&T Presspart has 3 European manufacturing sites and sales offices in China, India, the U.S.A. and Uruguay. For more information, please visit www.presspart.com
About Heitkamp & Thumann Group
The Heitkamp & Thumann Group is a leading global partner for the supply of world class precision formed components in both metal and plastic. The family-owned Group comprises of 14 medium-sized companies located in 8 different countries. Efficiency, quality, and innovation have always been at the very center of our corporate philosophy and entrepreneurial activities. Highly qualified and motivated employees and lean structures make us successful all over the world. For more information, please visit www.ht-group.com